MedPath

BRISTOL MYERS SQUIBB

๐Ÿ‡ซ๐Ÿ‡ทFrance
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Phase 1
Completed
Conditions
Multiple Myeloma
Interventions
First Posted Date
2014-09-30
Last Posted Date
2017-11-01
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
44
Registration Number
NCT02252263
Locations
๐Ÿ‡ช๐Ÿ‡ธ

Local Institution, Pamplona, Navarra, Spain

๐Ÿ‡บ๐Ÿ‡ธ

The Ohio State University, Columbus, Ohio, United States

๐Ÿ‡บ๐Ÿ‡ธ

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C

Completed
Conditions
Chronic Hepatitis C
First Posted Date
2014-09-26
Last Posted Date
2017-05-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
2974
Registration Number
NCT02250001
Locations
๐Ÿ‡ฏ๐Ÿ‡ต

Local Institution, Chuo-ku, Tokyo, Japan

BMS-986012 in Relapsed/Refractory SCLC

Phase 1
Completed
Conditions
Small Cell Lung Cancer
Interventions
Biological: BMS-986012 (anti-fucosyl-GM1)
Biological: Nivolumab
First Posted Date
2014-09-25
Last Posted Date
2024-03-05
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
106
Registration Number
NCT02247349
Locations
๐Ÿ‡ง๐Ÿ‡ช

Local Institution - 0015, Gent, Belgium

๐Ÿ‡ง๐Ÿ‡ช

Local Institution - 0012, Liege, Belgium

๐Ÿ‡ต๐Ÿ‡ท

Local Institution - 0009, San Juan, Puerto Rico

and more 13 locations

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Phase 3
Active, not recruiting
Conditions
Advanced Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Interventions
Biological: Nivolumab
Biological: Ipilimumab
Drug: Sunitinib
First Posted Date
2014-09-04
Last Posted Date
2023-11-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1390
Registration Number
NCT02231749
Locations
๐Ÿ‡ฎ๐Ÿ‡ฑ

Local Institution - 0120, Haifa, Israel

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0057, La Jolla, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Local Institution - 0067, Stanford, California, United States

and more 186 locations

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Phase 1
Completed
Conditions
Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)
Interventions
Drug: ND-L02-s0201 Injection
First Posted Date
2014-08-28
Last Posted Date
2017-05-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
25
Registration Number
NCT02227459
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Texas Liver Institute, Austin, Texas, United States

๐Ÿ‡ง๐Ÿ‡ฌ

Tokuda Hospital, Sofia, Bulgaria

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

Phase 1
Completed
Conditions
Drug-drug Interaction Study
Interventions
First Posted Date
2014-08-27
Last Posted Date
2014-11-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
20
Registration Number
NCT02227173
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Healthcare Discoveries, LLC d/b/a ICON Development Solutions, San Antonio, Texas, United States

YERVOYยฎ Risk Minimization Tool Effectiveness Evaluation Survey

Completed
Conditions
Advanced Melanoma
Interventions
First Posted Date
2014-08-25
Last Posted Date
2015-12-21
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
158
Registration Number
NCT02224768
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Local Institution, St. Ives, Cambridgeshire, United Kingdom

๐Ÿ‡บ๐Ÿ‡ธ

Bristol-Myers Squibb, Princeton, New Jersey, United States

Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens

Completed
Conditions
HIV Infection
First Posted Date
2014-08-08
Last Posted Date
2014-10-15
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
11400
Registration Number
NCT02211807

A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects

Phase 1
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: BMS-986104
Drug: Placebo
First Posted Date
2014-08-07
Last Posted Date
2015-09-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
41
Registration Number
NCT02211469
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

Phase 1
Completed
Conditions
Healthy Adult Volunteers
Interventions
Drug: BMS-986120
Drug: Placebo
Drug: Midazolam
First Posted Date
2014-08-05
Last Posted Date
2015-07-07
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
24
Registration Number
NCT02208882
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Ppd Development, Lp, Austin, Texas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath